Our VIP-receptor antagonists have demonstrated efficacy and safety in several animal models of AML, PDAC and melanoma.
Founded in 2018, by Ned Waller, MD, PhD, FACP, Cambium Oncology’s first-in-class antagonist blocks VIP signaling to reestablish immune surveillance and defeat cancers.
Learn about our technology
Cambium Oncology is developing first-in-class immunotherapies targeting neuroimmune checkpoints, including ANT308 and CAMV-01, antagonists of VIP/VPAC axis. Our company was founded on intellectual property licensed from Emory University.
Our approach focuses on biomarker-driven patient selection — identifying tumors with high VIP or VPAC expression — and rational combinations with PD-1 blockers.
We’ve built a clear de-risking strategy: robust preclinical proof-of-concept, early pharmacodynamic biomarkers, and careful safety monitoring given VIP’s role in immune regulation.
Team
Our team comprises seasoned, accomplished, and committed scientists, physicians, and business executives, all dedicated to delivering transformative medications to cancer patients and generating substantial returns for our stakeholders. Our partnership with the Winship Cancer Center at Emory University significantly augments our capabilities in drug research and development, clinical trial design and execution, regulatory clearance, and market launch.
Meet our Team